News | Artificial Intelligence | March 05, 2020

CLEW Brings Groundbreaking AI-Powered Critical Care Solution to U.S. Market

As Covid-19 spreads, healthcare resources — especially in ICUs will be pressured. Limited resources will need to be strategically leveraged/managed, and AI/predictive analytics may hold the key.

CLEW announced that it will be demonstrating the industry’s first-ever AI-powered critical care solution

March 5, 2020 — CLEW announced that it will be demonstrating the industry’s first-ever AI-powered critical care solution at two major industry tradeshows: The Society of Critical Care Medicine’s (SCCM) 49th Critical Care Congress, Feb. 16-19, and at the HIMSS Conference, March 9-13. Both healthcare events are taking place in Orlando, Fla.

Clinicians at UMass and WakeMed are testing the use of AI/predictive analytics to risk-stratify ICU patients by acuity to optimize patient flows and deployment of clinical resources. CLEW is the first technology to provide clinical predictive intelligence 6-14 hours in advance. Pending FDA approved (filing completed), this technology represents the innovation healthcare system need to optimize scarce healthcare resources—every day and during a crisis.

The CLEW solution harnesses vast amounts of clinical and patient data in real-time to deliver highly accurate predictive clinical analytics. Using prediction models CLEW provides ICU and TeleICU providers with preemptive patient care information, enabling continuous patient risk stratification, acuity-based resource allocation, clinical optimization, and improved case volumes.

Commenting on the need for a meaningful breakthrough in the delivery of healthcare, CLEW founder and CEO Gal Salomon said, “Using artificial intelligence is the only way to create change that really moves the needle to deliver true patient value.  With its U.S. market launch, CLEW aims to help U.S. health systems improve clinical outcomes and the patient experience by shortening stays and improving efficiency while reducing costs.

Craig Lilly, M.D., vice-chair, Critical Care Operations and Director of the eICU program at UMass Memorial commented on the use of AI in critical care, “Rather than reacting or having alerts and alarms in the room that tells us that a patient is deteriorating, we know ahead of time so that we can intervene in a way that prevents the patient from ever having any symptoms in the first place. It's truly an advance.”

For more information: www.clewmed.com/

Related Content

Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...
AI-powered premium large bore CT scanner offers industry’s largest bore and widest field-of-view
News | Computed Tomography (CT) | October 24, 2020
October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S.
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...